Summary of studies reporting adverse respiratory infections events
| First author [ref.] | Study design | Total subjects | Subjects with LAM | Subjects who withdrew | Mean % predicted FEV1 | Treatment | Length of follow-up years | Risk of bias |
| Treatment | ||||||||
| Bissler [8] | NROL | 25 | 18 | 5 | 57.2 | Sirolimus | 1.0 | Low |
| Dabora [9] | NROL | 36 | 21 | 8 | # | Sirolimus | 1.0 | Low |
| Davies [10] | NROL | 16 | 9 | 6 | 56.9 | Sirolimus | 2.0 | Low |
| Neurohr [13] | NROL/RC | 10 | 10 | 3 | 36.1 | Sirolimus | 1.0¶ | Serious |
| McCormack [3] | RPC | 46 | 46 | 5 | 49.3 | Sirolimus | 1.0 | Low |
| Ando [15] | RC | 15 | 15 | 0 | # | Sirolimus | 1.4¶ | Critical |
| Bissler [5] | RPC | 79 | 22 | 7 | # | Everolimus | 0.7¶ | Low |
| Mohammadieh [14] | NROL/RC | 5 | 5 | 0 | NR | Everolimus | 0.5 | Serious |
| Goldberg [11] | NROL | 24 | 24 | 7 | 60.4 | Everolimus | 1.2 | Low |
| Yao [12] | NROL | 38 | 38 | 0 | 72.1 | Sirolimus | 3.4¶ | Low |
| Placebo | ||||||||
| McCormack [3] | RPC | 43 | 43 | 7 | 47.7 | Placebo | 1.0 | Low |
| Bissler [5] | RPC | 39 | 7 | 13 | # | Placebo | 0.6 | Low |
| Chang [4] | RPC | 11 | 11 | 4 | 64.0 | Placebo | 2.0 | Low |
| All studies | ||||||||
| Total | 387 | 269 | 68 | |||||
| Mean±sd | 1.4±0.8 |
LAM: lymphangioleiomyomatosis; FEV1: forced expiratory volume in 1 s; NROL: non-randomised open label; RC: retrospective cohort; RPC: randomised placebo controlled. #: reported as absolute FEV1 or relative change in FEV1 rather than % predicted FEV1; ¶: reported as mean or median follow-up.